Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, Ro60-associated Y1 pseudogene 9 (RNY1P9) is a non-protein coding transcript classified as a pseudogene related to the RNY1 gene, which encodes Ro-associated Y RNA involved in ribonucleoprotein complexes[5]. Pseudogenes like RNY1P9 typically arise from duplication or retrotransposition events and usually do not produce functional proteins; their main biological effects are often regulatory, such as acting as competitive endogenous RNAs (ceRNAs) or miRNA sponges in post-transcriptional regulation[4]. RNY1P9 is annotated as an intronic noncoding transcript from the KLHL22 gene region but is not itself a receptor, enzyme, or other conventional drug target. There is no published evidence assigning a canonical therapeutic role, direct involvement in disease, or known drug interaction. The available evidence does not suggest any utility as a biomarker or any safety concern. Most current knowledge on pseudogenes is extrapolated from other family members, and primary function or clinical importance is likely null or unknown for RNY1P9 specifically[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, Ro60-associated Y1 pseudogene 9 (RNY1P9).